Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > °¨¿°Áúȯ > Opportunities Assessment for Hepatitis B Therapeutics in Thailand
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4920)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (180)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1520)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (85)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (522)
󹿾à (165)
½ÃÀ庸°í¼­

Opportunities Assessment for Hepatitis B Therapeutics in Thailand

¸®¼­Ä¡»ç Frost & Sullivan
¹ßÇàÀÏ 2009³â 03¿ù »óǰÄÚµå 83699
ÆäÀÌÁö Á¤º¸ 37 Pages
°¡°Ý
US $ 6,000 £Ü 7,103,400 Web Access (Regional License)
US $ 6,500 £Ü 7,695,300 Hard Copy & Web Access (Regional License)


¿µ¹®¸ñÂ÷

Abstract

This research service aims to provide an update on the epidemiology of hepatitis B, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the diabetes therapeutics market in Thailand.

Table of Contents

1. EXECUTIVE SUMMARY

Market Overview

  • Hepatitis B Therapeutics Executive Summary

2. HEPATITIS B THERAPEUTICS MARKET

Market Overview

  • Introduction
  • Context for the Study
  • Geographic Scope and Methodology
  • Restraints in Forecasts

3. THAI HEPATITIS B THERAPEUTICS MARKET

Market Overview

  • Introduction
  • Market Engineering Measurements
  • Government Initiatives

Market Forecasts and Trends

  • Patient Forecasts
  • Cost of Treatment

Treatment and Diagnosis

  • Key Treaters and Patient Flow
  • Diagnostic Tests
  • Treatment Options
  • Duration of Treatment

Product Launches

  • Launched Products

Clinical Trials

  • Products in Clinical Trials

Competitive Analysis

  • Competitive Structure
  • Market Share Analysis
  • Future Trends
  • Challenges Faced by Physicians

4. APPENDIX

Appendices Hepatitis B Thailand

  • Total Population and Growth Rate
  • Access Population and Percent of Total Population
  • Carriers of HBV and Percent of Access Population
  • Total CHB Patients and Percent of Carriers of HBV
  • Diagnosed Patients and Percent of CHB Patients
Back to Top